Earnings Forecast Research on Portola Pharmaceuticals, Inc. (PTLA)

Portola Pharmaceuticals, Inc. has received $-1.1 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 3 Financial Advisor in the Stock Trading Firms. Among 3 Analysts, Bottom line EPS Estimate for the current quarter is $-1.34 while the top line estimate is $-0.87 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 10.57%.

Portola Pharmaceuticals, Inc. results fell short with a surprise EPS of -51.85% or $-0.56. The Actual EPS was $-1.64 compared to the Estimated EPS of $-1.08 during its most recent quarterly earnings.

In the last quarter, Portola Pharmaceuticals, Inc. reported Annual Earnings of $-1.64. Based on the filings, last years Annual Earnings was, $-4.36. In the last Quarter, PTLA reported a surprise Earnings per Share of -51.85% . The consensus estimate for current quarter is $-1.1 and for the current fiscal year, the estimate is $-4.92. For the Next fiscal year, the estimate is $-4.26 based on the consensus.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) : On Tuesday heightened volatility was witnessed in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) which led to swings in the share price. The stock opened for trading at $25.22 and hit $27.8 on the upside , eventually ending the session at $27.25, with a gain of 6.7% or 1.71 points. The heightened volatility saw the trading volume jump to 1,278,759 shares. The 52-week high of the share price is $35.32 and the company has a market cap of $1,541 million. The 52-week low of the share price is at $15.68 .

Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California.

Portola

Share this post

Leave a Reply